LIFE - aTYR PHARMA INC

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 1.61

Open

$ 1.60

Bid

$ 1.59 x 100

Ask

$ 0.00 x 0

Day's Range

$ 1.58 - $ 1.62

52 Week Range

$ 1.08 - $ 2.70

Volume

258,232

Average Volume

Market Cap

106.39M

Beta (5Y Monthly)

$ 1.11

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	03-14-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-14-2023	12-31-2022	10-K
7	11-14-2022	09-30-2022	10-Q
8	08-15-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-15-2022	12-31-2021	10-K
11	11-12-2021	09-30-2021	10-Q
12	08-11-2021	06-30-2021	10-Q
13	05-14-2021	03-31-2021	10-Q
14	03-24-2021	12-31-2020	10-K
15	11-13-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	05-12-2020	03-31-2020	10-Q
18	03-26-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q
20	08-14-2019	06-30-2019	10-Q
21	05-14-2019	03-31-2019	10-Q
22	03-26-2019	12-31-2018	10-K
23	11-14-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q
25	05-15-2018	03-31-2018	10-Q
26	03-20-2018	12-31-2017	10-K
27	11-14-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-11-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-10-2016	06-30-2016	10-Q
33	05-11-2016	03-31-2016	10-Q
34	03-30-2016	12-31-2015	10-K
35	11-10-2015	09-30-2015	10-Q
36	08-12-2015	06-30-2015	10-Q
37	06-18-2015	03-31-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on aTyr...
05/03/2024 19:55:21

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

aTyr Pharma Q1 EPS $(0.23) Beats $(0.24) E...
05/02/2024 20:27:04

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) b...

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 20:31:18

RBC Capital Maintains Outperform on aTyr P...
03/15/2024 16:49:46

RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19...

HC Wainwright & Co. Reiterates Buy on aTyr...
03/15/2024 10:20:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

Recap: aTyr Pharma Q4 Earnings
03/14/2024 20:15:11

aTyr Pharma Q4 2023 GAAP EPS $(0.25) Misse...
03/14/2024 20:14:09

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24)...

Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

aTyr Pharma's Earnings Outlook
03/13/2024 17:01:48

HC Wainwright & Co. Reiterates Buy on aTyr...
02/21/2024 16:16:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

aTyr Pharma Announces Expanded Access Prog...
02/21/2024 13:06:23

aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and deve...

aTyr Pharma Presents Posters For Neuropili...
01/29/2024 13:18:39

Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique...

ATyr Pharma 13G Filing Shows Logos Global ...
01/02/2024 17:28:06

- SEC Filing

aTyr Pharma Presents Poster Demonstrating ...
11/13/2023 13:28:36

aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

aTyr Pharma Q3 EPS $(0.20) Beats $(0.23) E...
11/09/2023 21:46:43

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) b...

aTyr Pharma Announces Dosing Of First Pati...
10/31/2023 12:05:31

aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and deve...

Stocks That Hit 52-Week Lows On Tuesday
10/03/2023 18:37:58

On Tuesday, 647 companies set new 52-week lows.

Analyst Expectations for aTyr Pharma's Future
09/21/2023 16:00:24

HC Wainwright & Co. Reiterates Buy on aTyr...
09/21/2023 10:22:54

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

HC Wainwright & Co. Reiterates Buy on aTyr...
09/14/2023 10:08:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...